PepGen (NASDAQ:PEPG) Sees Strong Trading Volume

PepGen Inc. (NASDAQ:PEPG) shares saw an uptick in trading volume on Friday . 137,180 shares changed hands during trading, an increase of 36% from the previous session’s volume of 100,572 shares.The stock last traded at $16.45 and had previously closed at $16.46.

Analysts Set New Price Targets

A number of research firms recently weighed in on PEPG. Wedbush reaffirmed an “outperform” rating and issued a $20.00 price target on shares of PepGen in a report on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 target price on shares of PepGen in a research note on Wednesday, May 15th.

PepGen Price Performance

The business’s 50 day moving average price is $14.92 and its 200 day moving average price is $12.39. The firm has a market cap of $517.42 million, a PE ratio of -5.06 and a beta of 1.76.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.11. As a group, analysts predict that PepGen Inc. will post -2.87 earnings per share for the current year.

Insider Activity at PepGen

In other news, SVP Niels Svenstrup sold 10,000 shares of the firm’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $13.41, for a total value of $134,100.00. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, SVP Niels Svenstrup sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $13.41, for a total value of $134,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michelle L. Mellion sold 9,260 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $18.19, for a total value of $168,439.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 19,760 shares of company stock valued at $311,559. 4.60% of the stock is owned by insiders.

Institutional Investors Weigh In On PepGen

A number of hedge funds and other institutional investors have recently modified their holdings of PEPG. Adage Capital Partners GP L.L.C. increased its holdings in PepGen by 18.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 680,000 shares of the company’s stock valued at $3,454,000 after buying an additional 105,000 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of PepGen by 68.0% during the 1st quarter. Vanguard Group Inc. now owns 850,445 shares of the company’s stock worth $12,502,000 after acquiring an additional 344,266 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of PepGen by 18.1% in the 1st quarter. Janus Henderson Group PLC now owns 1,166,642 shares of the company’s stock valued at $17,225,000 after acquiring an additional 178,438 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of PepGen during the 1st quarter worth about $30,000. Finally, RA Capital Management L.P. raised its position in shares of PepGen by 31.5% during the 1st quarter. RA Capital Management L.P. now owns 10,689,545 shares of the company’s stock worth $157,136,000 after acquiring an additional 2,557,593 shares in the last quarter. 58.01% of the stock is currently owned by institutional investors and hedge funds.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.